THERAPY DOSSIER · th-92499df23699

Dextrorphan (non-competitive NMDA antagonist) and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (competitive NMDA antagonist)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL1254766 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Dextrorphan; Dextrorfano; Dextrorphane; Dextro-dromoran; D-levorphanol; RO 1-6794
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 2567056 ↗1989Reported benefit

The role of excitatory amino acids and NMDA receptors in traumatic brain injury.

RatTBIFluid percussionMaleAfter injury

Model: Fluid percussion traumatic brain injury

Injury raised extracellular glutamate and aspartate in proportion to severity, with reduced bioenergetic state and intracellular free magnesium. Both NMDA antagonists limited neurological dysfunction, and dextrorphan also improved bioenergetic state and intracellular free magnesium.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…